Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

施觅福 - NMPA Drug Approval Details

Approvals/NMPA/Peficitinib Hydrobromide Tablets

Approved

化学药品

Peficitinib Hydrobromide Tablets

ASTELLAS PHARMA INC.🇨🇳 National Medical Products Administration

Approval Date: Aug 28, 2024
Approval ID: 8btvVU8gEQL
Company: ASTELLAS PHARMA INC.
Type: 化学药品

Approval Details

Approval Id: 8btvVU8gEQL
Approval Number: 国药准字HJ20240076
Generic Name: 氢溴酸吡西替尼片
Generic Name En: Peficitinib Hydrobromide Tablets
Trade Name: 施觅福
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 50mg(以C₁₈H₂₂N₄O₂计）
Reg Date: 2024-08-28
Expired Date: 2029-07-29
Company Name: ASTELLAS PHARMA INC.
Company Detail Path: /organization/astellas-pharma-inc

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Aug 28, 2024

Approval ID

8btvVU8gEQL

Type

化学药品

Back to NMPA Approvals